NVS · Novartis AG · Webcasts, Transcripts & Audio
$160.50
+0.25 (+0.16%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$303.12B
Shares
1.89B
Volume · Nov 13
1.42M
Avg daily vol (3M)
2.11M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Novartis AG Webcasts
Earnings calls, investor updates, investor days and conferences for Novartis AG (NVS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q4
2027-02-03
Novartis AG (NVS) Q4 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-11-10
Novartis AG (NVS) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-27
Novartis AG (NVS) Q3 2026 Earnings Call Transcript
Confident tone
Guidance upgrade and sales outlook
Capital allocation and shareholder returns
Margin, productivity and generic erosion
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-21
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Diluted EPS
$1.71
▼ 17% YoY
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Novartis AG (NVS) Q1 2026 Earnings Call Transcript
Confident tone
China and ex-US dynamics
MFN and pricing environment
Avidity acquisition
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-04
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Confident tone
Kisqali growth and peak sales outlook
Remibrutinib and pelabresib pipeline progress
Avidity acquisition / SG&A and margin dilution
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Confident tone
Full-year 2025 guidance and margin outlook
Generic erosion of legacy brands
Late-stage pipeline and approvals
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Confident tone
Priority brands momentum
Topline and margin growth
Entresto generic risk and IP defense
Diluted EPS
$2.06
▲ 29.6% YoY
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Confident tone
Kisqali momentum in metastatic and early breast cancer
Pluvicto PSMAfore launch and radioligand expansion
Pipeline and regulatory milestones
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Confident tone
Key growth brands (Cosentyx, Kesimpta, Kisqali)
Pluvicto and radioligand therapy (RLT) pipeline
Pipeline readouts and innovation momentum
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Confident tone
Kisqali early breast cancer launch
Entresto growth and loss of exclusivity
IRA legislation and siRNA policy
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Novartis AG (NVS) Q2 2024 Earnings Call Transcript
Confident tone
Growth drivers and brand momentum
Pluvicto / radioligand therapy
Remibrutinib manufacturing delay
Diluted EPS
$1.59
▲ 43.2% YoY
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Novartis AG (NVS) Q1 2024 Earnings Call Transcript
Confident tone
Leqvio geographic ramp
Cosentyx and new indications
Kisqali and early breast cancer
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Novartis AG (NVS) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Novartis AG (NVS) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Novartis AG (NVS) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 webcasts
Key facts
CIK
1114448
CUSIP
66987V109
13F (30d)
1276 filings
1161 filers
Visit website
Investor relations